CapitolRadar tracks every publicly disclosed VRTX trade by US congress members and corporate insiders: 31 disclosed trades (19 buys, 12 sells) by 4 tracked traders, from 2019-04-11 to 2026-09-04. Updated daily from official filings.
Want a ping when Congress buys VRTX? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Vertex Pharmaceuticals Incorporated (VRTX) — Healthcare · Biotechnology, market cap about $123.8B.
CapitolRadar analysis
31 tracked VRTX trades split 19 buys to 12 sells
Vertex Pharmaceuticals Incorporated (VRTX), a Healthcare / Biotechnology company, has 31 tracked trades from April 11, 2019 through September 4, 2026. The activity comprises 19 buys and 12 sells across four distinct traders. Buys therefore outnumber sells by seven, although the four-trader sample is small and does not support broad conclusions about trading sentiment.
Buying is highly concentrated among the disclosed names: Ro Khanna accounts for 18 of the 19 tracked buys, with the latest dated September 4, 2026. Tommy Tuberville accounts for one buy, dated October 6, 2022. The provided facts do not identify the other two traders or attribute any buys to them.
6 trades in 2025 Q3 mark the largest listed quarter
Among the quarters provided, 2025 Q3 has the most activity, with six trades split evenly between three buys and three sells. The listed 2026 activity includes two trades in Q3, one of them a buy, and one trade in Q2, also a buy. Other listed quarters are smaller: one buy in 2024 Q4, one buy in 2024 Q3, one sell in 2024 Q2, one buy in 2023 Q4, and two buys in 2023 Q2.
These quarterly entries cover only part of the 31-trade history supplied, so they should not be read as a complete quarter-by-quarter distribution. Several quarters contain only one or two observations, making quarter-level comparisons especially sensitive to the small sample.
6 additional tickers overlap with one VRTX buyer
One of the VRTX buyers also bought each of ALIZY, AVGO, BSX, CMCSA, CTAS and DXCM. The data does not specify which buyer made those purchases, their timing or their size, so the overlap establishes only shared buyer activity.
Congressional disclosures can be filed up to 45 days after a transaction, meaning reported activity may lag the trade date. Transaction amounts, when presented as disclosure ranges, are estimates rather than exact values; no amount ranges are provided here.
Analysis written from the tracked record on 2026-10-13; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 2 | 1 | 1 |
| 2026 Q2 | 1 | 1 | 0 |
| 2025 Q3 | 6 | 3 | 3 |
| 2024 Q4 | 1 | 1 | 0 |
| 2024 Q3 | 1 | 1 | 0 |
| 2024 Q2 | 1 | 0 | 1 |
| 2023 Q4 | 1 | 1 | 0 |
| 2023 Q2 | 2 | 2 | 0 |
Who is buying VRTX?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Ro Khanna | 18 | 2026-09-04 | — |
| Tommy Tuberville | 1 | 2022-10-06 | — |
Disclosed trades in VRTX
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-04 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2026-08-26 | David Taylor | sell | $1,001 - $15,000 | — |
| 2026-04-13 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2025-09-29 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2025-09-05 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2025-08-26 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2025-08-26 | Ro Khanna | sell | $1,000 - $15,000 | — |
| 2025-08-04 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2025-08-04 | Ro Khanna | buy | $1,000 - $15,000 | — |
| 2024-11-15 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-09-09 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-05-03 | Tommy Tuberville | sell | $1,001 - $15,000 | — |
| 2023-10-02 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-06-29 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-05-23 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-03-24 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-03-14 | Ro Khanna | sell | $1,001 - $15,000 | — |
| 2023-02-10 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-01-11 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2023-01-09 | Ro Khanna | buy | $1,001 - $15,000 | — |
These buyers also bought
Other stocks the tracked buyers of VRTX disclosed buying in the last six months: FCX (1) · HON (1) · JNJ (1) · LVS (1) · MRSH (1) · ODFL (1).
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a r…
Frequently asked questions
Which politicians bought VRTX most?
Ro Khanna leads with 18 disclosed buys, followed by Tommy Tuberville.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.